EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Capless self-amplifying mRNA vaccine induces dose-sparing protective immunity against HPAI clade 2.3.4.4 H5 virus in mice

Beom Kyu Kim, Ji-Hyun Park, Won-Suk Choi, Sol Oh, Se Hee An, Gi Chan Lee, Santosh Chokkakula, Chang-Ung Kim, Ju Hwan Jeong, Seong Cheol Min, Dong Gyu Lee, Ju Ryeong Lee und 7 weitere

Molecular Therapy · 2026-10 · 34 (10) · 6007-6027

DOI: 10.1016/j.ymthe.2026.07.047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026-10. Verfasst von Beom Kyu Kim und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Chungbuk National University Medical School, Cheongju 28644, Republic of Korea; Microuni, Co. Ltd., Cheongju, Chungbuk 28…. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza A Virus, H5N1 Subtype, mRNA Vaccines, Orthomyxoviridae Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute for Basic Science, Coalition for Epidemic Preparedness Innovations, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Self-amplifying mRNA (samRNA) vaccines can induce potent immune responses at lower doses than conventional non-replicating mRNA vaccines; however, large RNA size and manufacturing considerations associated with 5' capping remain important challenges. Here, we developed a capless samRNA (CLsamRNA) vaccine platform derived from a Coxsackievirus B5 replicon that uses internal ribosome entry site-mediated cap-independent translation. Systematic optimization of key genetic elements enhanced antigen expression from the CLsamRNA backbone. Using reporter RNAs, LNP-formulated CLsamRNA showed rapid early expression and RNA amplification, with expression kinetics distinct from VEEV-based saRNA and nucleoside-modified mRNA comparators. When encoding the hemagglutinin antigen of highly pathogenic avian influenza clade 2.3.4.4 H5 viruses, CLsamRNA induced potent immune responses after LNP formulation. In mouse models, CLsamRNA induced potent neutralizing antibody responses, cross-reactive activity against clade 2.3.4.4b H5N1 virus, Th1-skewed humoral immunity, and strong antigen-specific cellular immune responses. CLsamRNA also elicited platform-specific early inflammatory and lymph node immune gene signatures associated with antigen presentation, costimulation, and cellular immune priming. Notably, a minimal 0.01-μg dose of CLsamRNA conferred complete protection against lethal H5N8 influenza virus challenge in BALB/c mice. These findings support CLsamRNA as a distinct cap-independent RNA vaccine platform with dose-sparing protective efficacy against highly pathogenic avian influenza H5 viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza A Virus, H5N1 SubtypemRNA VaccinesOrthomyxoviridae InfectionsRNA, MessengerAnimalsMiceAntibodies, ViralAntibodies, NeutralizingFemaleMice, Inbred BALB CHumans

Stichwörter der Autor:innen

CLsamRNAHPAI H5 vaccineIREScapless self-amplifying mRNAenterovirus repliconlipid nanoparticle

Substanzen

Influenza VaccinesAntibodies, ViralAntibodies, NeutralizingmRNA VaccinesRNA, Messenger

Autor:innen und Institutionen

  • Department of Microbiology, Chungbuk National University Medical School, Cheongju 28644, Republic of Korea; Microuni, Co. Ltd., Cheongju, Chungbuk 28160, Republic of Korea.
  • Department of Microbiology, Chungbuk National University Medical School, Cheongju 28644, Republic of Korea.
  • College of Pharmacy, Chosun University, Gwangju 61452, Republic of Korea.
  • Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Jeongeup 56212, Republic of Korea.
  • Department of Vaccine Biotechnology, College of Life Sciences and Health Welfare, Gyeongkuk National University, Andong 36729, Republic of Korea.
  • Department of Microbiology, Chungbuk National University Medical School, Cheongju 28644, Republic of Korea; Chungbuk National University Hospital, Chungdae-ro 1, Seowon-gu, Cheongju 28644, Republic of Korea.

Förderung

  • Institute for Basic Science
  • Coalition for Epidemic Preparedness Innovations
  • National Research Foundation of Korea
  • Korea Ministry of Science and ICT

Zitieren

APA

Kim, B. K., Park, J. H., Choi, W. S., Oh, S., An, S. H., Lee, G. C., Chokkakula, S., Kim, C. U., Jeong, J. H., Min, S. C., Lee, D. G., Lee, J. R., Yoon, S. W., Kim, D. J., Mahony, T. J., Webby, R. J., Choi, Y. K., Baek, Y. H., & Song, M. S. (2026). Capless self-amplifying mRNA vaccine induces dose-sparing protective immunity against HPAI clade 2.3.4.4 H5 virus in mice. Molecular Therapy, 34(10), 6007-6027. https://doi.org/10.1016/j.ymthe.2026.07.047

Vancouver

Kim BK, Park JH, Choi WS, Oh S, An SH, Lee GC, et al. Capless self-amplifying mRNA vaccine induces dose-sparing protective immunity against HPAI clade 2.3.4.4 H5 virus in mice. Molecular Therapy. 2026;34(10):6007-6027. doi:10.1016/j.ymthe.2026.07.047

BibTeX
@article{Kim2026,
  author = {Kim, Beom Kyu and Park, Ji-Hyun and Choi, Won-Suk and Oh, Sol and An, Se Hee and Lee, Gi Chan and Chokkakula, Santosh and Kim, Chang-Ung and Jeong, Ju Hwan and Min, Seong Cheol and Lee, Dong Gyu and Lee, Ju Ryeong and Yoon, Sun-Woo and Kim, Doo-Jin and Mahony, Timothy J and Webby, Richard J and Choi, Young Ki and Baek, Yun Hee and Song, Min-Suk},
  title = {Capless self-amplifying mRNA vaccine induces dose-sparing protective immunity against HPAI clade 2.3.4.4 H5 virus in mice},
  journal = {Molecular Therapy},
  year = {2026},
  volume = {34},
  number = {10},
  pages = {6007--6027},
  doi = {10.1016/j.ymthe.2026.07.047}
}
Kostenlos starten →